StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Perspective Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$121.19M. For fiscal 2025 it was -$95.23M. The highest annual figure on record is -$2.50M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$95.23M–
FY2024Dec 31, 2024-$72.71M–
FY2022Jun 30, 2022-$7.98M–
FY2021Jun 30, 2021-$3.22M–
FY2020Jun 30, 2020-$3.91M–
FY2019Jun 30, 2019-$5.49M–
FY2018Jun 30, 2018-$6.05M–
FY2017Jun 30, 2017-$6.26M–
FY2016Jun 30, 2016-$4.36M–
FY2015Jun 30, 2015-$3.66M–
FY2014Jun 30, 2014-$3.25M–
FY2013Jun 30, 2013-$3.06M–
FY2012Jun 30, 2012-$2.50M–
FY2011Jun 30, 2011-$2.56M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$34.85M–
Q1 FY2026CQ1 2026Mar 31, 2026-$38.33M–
Q4 FY2025CQ4 2025Dec 31, 2025-$29.73M–
Q3 FY2025CQ3 2025Sep 30, 2025-$18.28M–
Q2 FY2025CQ2 2025Jun 30, 2025-$20.98M–
Q1 FY2025CQ1 2025Mar 31, 2025-$26.24M-649.4%
Q4 FY2024CQ4 2024Dec 31, 2024-$41.22M–
Q3 FY2024CQ3 2024Sep 30, 2024-$26.35M–
Q2 FY2024CQ2 2024Jun 30, 2024-$9.92M–
Q1 FY2024CQ1 2024Mar 31, 2024$4.78M–
Q4 FY2022CQ2 2022Jun 30, 2022-$3.00M–
Q3 FY2022CQ1 2022Mar 31, 2022-$1.45M–
Q2 FY2022CQ4 2021Dec 31, 2021-$1.39M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.14M–
Q4 FY2021CQ2 2021Jun 30, 2021-$1.23M–
Q3 FY2021CQ1 2021Mar 31, 2021-$714.00K–
Q2 FY2021CQ4 2020Dec 31, 2020-$820.00K–
Q1 FY2021CQ3 2020Sep 30, 2020-$451.00K–
Q4 FY2020CQ2 2020Jun 30, 2020-$873.00K–
Q3 FY2020CQ1 2020Mar 31, 2020-$906.00K–
Q2 FY2020CQ4 2019Dec 31, 2019-$1.38M–
Q1 FY2020CQ3 2019Sep 30, 2019-$751.00K–
Q4 FY2019CQ2 2019Jun 30, 2019-$1.08M–
Q3 FY2019CQ1 2019Mar 31, 2019-$1.47M–
Q2 FY2019CQ4 2018Dec 31, 2018-$1.23M–
Q1 FY2019CQ3 2018Sep 30, 2018-$1.73M–
Q4 FY2018CQ2 2018Jun 30, 2018-$1.55M–
Q3 FY2018CQ1 2018Mar 31, 2018-$1.16M–
Q2 FY2018CQ4 2017Dec 31, 2017-$1.62M–
Q1 FY2018CQ3 2017Sep 30, 2017-$1.72M–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.47M–
Q3 FY2017CQ1 2017Mar 31, 2017-$1.54M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.75M–
Q1 FY2017CQ3 2016Sep 30, 2016-$1.50M–
Q4 FY2016CQ2 2016Jun 30, 2016-$1.43M–
Q3 FY2016CQ1 2016Mar 31, 2016-$981.00K–
Q2 FY2016CQ4 2015Dec 31, 2015-$842.00K–
Q1 FY2016CQ3 2015Sep 30, 2015-$1.11M–
Q4 FY2015CQ2 2015Jun 30, 2015-$684.57K–
Q3 FY2015CQ1 2015Mar 31, 2015-$1.16M–

More Perspective Therapeutics figures

See a number that looks wrong?